Table 2. Patient characteristics (per protocol analysis).
| Variable | Treatmentgroup (n = 11) | Control(n = 11) | p-value(betweengroup)* |
| Sex (m/f) | 9/2 | 8/3 | 1.000 |
| Age (years) | 71.09±5.47 | 65.09±12.55 | 0.408 |
| Weight (kg) | 84.64±11.68 | 83.91±12.89 | 0.592 |
| Height (cm) | 174.09±6.79 | 172.64±6.90 | 0.834 |
| ECOG at baseline (0/1/2) | 6/4/1 | 4/5/2 | 0.370 |
| EQ5D visual analogue score | 72.36±14.56 | 76.36±13.02 | 0.446 |
| History of liver surgery | 45.5% | 45.5% | 1.000 |
| Steatosis hepatis | 36.4% | 18.2% | 0.635 |
| Diabetes mellitus | 18.2% | 27.3% | 1,000 |
| Chemotherapy pretreatment | |||
| Applied lines | 1.00±0.63 | 1.00±0.45 | 1.000 |
| no chemotherapy | 18.2% | 9.1% | NA |
| 1 line | 63.6% | 81.8% | 0.672 |
| 2 lines | 18.2% | 9.1% | NA |
| Prior chemotherapy | |||
| Oxaliplatin | 63.6% | 63.6% | 1.000 |
| Irinotecan | 36.4% | 36.4% | 1.000 |
| Biologicals | 54.5% | 54.5% | 1.000 |
| Number of treated metastases | 1.91±1.04 | 1.45±0.52 | 0.382 |
| Maximum diameter of metastases (mm) | 37.18±12.91 | 29.45±11.79 | 0.146 |
| Clinical target volume (cm3) | 42.82±29.26 | 31.36±37.14 | 0.156 |
| Number of used brachytherapy catheters | 3.18±1.78 | 2.27±1.74 | 0.079 |
| Liver volume (cm3) | 1296.1±226.6 | 1451.3±278.6 | 0.401 |
| Interval between BT and 6 weeks FU (days) | 43.91±4.76 | 45.09±4.68 | 0.757 |
| Interval between BT and 3 months FU (days) | 87.34±4.52 | 89.55±6.15 | 0.505 |
| Liver volume with a dose exposure >10 Gy (%) | 22.55±14.45 | 11.95±10.43 | 0.056 |
| Chemotherapy during follow-up | 18.2% | 9.1% | 1.000 |
Continuous data: mean ± standard deviation, frequencies: counts or percent.
*Group comparison, continuous data compared by Mann-Whitney U test, frequency data compared by Pearson’s chi square test.